Bullous fixed drug eruption following administration of the recombinant adjuvant Shingrix vaccine

A 51-year-old woman with Crohn’s disease presented with a bullous rash on her left arm and axilla 2 days after receiving her second dose of the recombinant adjuvant Shingrix vaccine. PCR for herpes simplex virus (HSV) 1, HSV 2 and varicella zoster virus was negative. Punch biopsy revealed changes th...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Hallie, Nichols, Laura, Gonzalez Santiago, Tania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378370/
https://www.ncbi.nlm.nih.gov/pubmed/34413031
http://dx.doi.org/10.1136/bcr-2020-241293
_version_ 1783740822495166464
author Thompson, Hallie
Nichols, Laura
Gonzalez Santiago, Tania
author_facet Thompson, Hallie
Nichols, Laura
Gonzalez Santiago, Tania
author_sort Thompson, Hallie
collection PubMed
description A 51-year-old woman with Crohn’s disease presented with a bullous rash on her left arm and axilla 2 days after receiving her second dose of the recombinant adjuvant Shingrix vaccine. PCR for herpes simplex virus (HSV) 1, HSV 2 and varicella zoster virus was negative. Punch biopsy revealed changes that were consistent with a bullous fixed drug eruption. She was successfully treated oral prednisone and topical triamcinolone cream. This is the first known case of a bullous fixed drug eruption due to the recombinant adjuvant Shingrix vaccine.
format Online
Article
Text
id pubmed-8378370
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-83783702021-09-02 Bullous fixed drug eruption following administration of the recombinant adjuvant Shingrix vaccine Thompson, Hallie Nichols, Laura Gonzalez Santiago, Tania BMJ Case Rep Case Report A 51-year-old woman with Crohn’s disease presented with a bullous rash on her left arm and axilla 2 days after receiving her second dose of the recombinant adjuvant Shingrix vaccine. PCR for herpes simplex virus (HSV) 1, HSV 2 and varicella zoster virus was negative. Punch biopsy revealed changes that were consistent with a bullous fixed drug eruption. She was successfully treated oral prednisone and topical triamcinolone cream. This is the first known case of a bullous fixed drug eruption due to the recombinant adjuvant Shingrix vaccine. BMJ Publishing Group 2021-08-19 /pmc/articles/PMC8378370/ /pubmed/34413031 http://dx.doi.org/10.1136/bcr-2020-241293 Text en © BMJ Publishing Group Limited 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Case Report
Thompson, Hallie
Nichols, Laura
Gonzalez Santiago, Tania
Bullous fixed drug eruption following administration of the recombinant adjuvant Shingrix vaccine
title Bullous fixed drug eruption following administration of the recombinant adjuvant Shingrix vaccine
title_full Bullous fixed drug eruption following administration of the recombinant adjuvant Shingrix vaccine
title_fullStr Bullous fixed drug eruption following administration of the recombinant adjuvant Shingrix vaccine
title_full_unstemmed Bullous fixed drug eruption following administration of the recombinant adjuvant Shingrix vaccine
title_short Bullous fixed drug eruption following administration of the recombinant adjuvant Shingrix vaccine
title_sort bullous fixed drug eruption following administration of the recombinant adjuvant shingrix vaccine
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378370/
https://www.ncbi.nlm.nih.gov/pubmed/34413031
http://dx.doi.org/10.1136/bcr-2020-241293
work_keys_str_mv AT thompsonhallie bullousfixeddrugeruptionfollowingadministrationoftherecombinantadjuvantshingrixvaccine
AT nicholslaura bullousfixeddrugeruptionfollowingadministrationoftherecombinantadjuvantshingrixvaccine
AT gonzalezsantiagotania bullousfixeddrugeruptionfollowingadministrationoftherecombinantadjuvantshingrixvaccine

Ejemplares similares